Why is Warner Bros. Discovery splitting into two companies?
How will US-China trade talks in London impact markets?
What caused Bitcoin transaction activity to hit a low?
Why did Trump deploy National Guard to Los Angeles protests?
How will OpenAI’s $10B revenue milestone affect AI industry?
What are the implications of Apple’s WWDC 2025 redesign?
Why did Tesla receive stock downgrades amid Musk-Trump feud?
Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial
benzinga.com/markets/biotech/25/06/45844751/avidity-biosciences-touts-encouraging-functional-gains-and-biomarker-reductions-in-rare-muscular-
Avidity Biosciences, Inc. (NASDAQ:RNA) revealed topline data from the dose escalation cohorts of the delpacibart braxlosiran (del-brax) Phase 1/2 FORTITUDE program in Facioscapulohumeral Muscular Dystrophy (FSHD).
FSHD is a genetically acquired disease that leads to progressive muscle…
This story appeared on benzinga.com, 2025-06-09 18:04:06.